Seres Therapeutics Inc MCRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MCRB is a good fit for your portfolio.
News
-
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
-
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
-
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
-
Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment
Trading Information
- Previous Close Price
- $0.97
- Day Range
- $0.98–1.07
- 52-Week Range
- $0.54–6.26
- Bid/Ask
- $1.00 / $1.02
- Market Cap
- $151.45 Mil
- Volume/Avg
- 2.1 Mil / 4.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 233
Comparables
Valuation
Metric
|
MCRB
|
AVIR
|
MORF
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.61 | 2.32 |
Price/Sales | 1.02 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MCRB
AVIR
MORF
Financial Strength
Metric
|
MCRB
|
AVIR
|
MORF
|
---|---|---|---|
Quick Ratio | 1.38 | 13.11 | 28.43 |
Current Ratio | 1.78 | 13.28 | 28.94 |
Interest Coverage | −8.19 | — | — |
Quick Ratio
MCRB
AVIR
MORF
Profitability
Metric
|
MCRB
|
AVIR
|
MORF
|
---|---|---|---|
Return on Assets (Normalized) | −22.71% | −20.62% | −18.85% |
Return on Equity (Normalized) | — | −21.76% | −19.43% |
Return on Invested Capital (Normalized) | −41.39% | −25.76% | −23.26% |
Return on Assets
MCRB
AVIR
MORF
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lmrwxgfph | Kspdw | $590.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Whkcclq | Wgjntc | $113.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hkbxzdn | Pfdxzr | $106.5 Bil | |
MRNA
| Moderna Inc | Dkxcbqkh | Qrybt | $58.7 Bil | |
BNTX
| BioNTech SE ADR | Xhvgttpck | Ttlgc | $23.8 Bil | |
ARGX
| argenx SE ADR | Lkwjfxqg | Ztsc | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hzltyrv | Dmrhpt | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fldmhtq | Lqjtbvm | $14.1 Bil | |
INCY
| Incyte Corp | Yxrbwwpsn | Vmkngjn | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xgvcglcmpx | Pmddvng | $12.4 Bil |